Professor Steve Henry
This project is a unique opportunity to rapidly establish the viability of a new approach to cancer therapeutics at a fraction of the current cost.
Every year more than 24,000 New Zealanders are diagnosed with cancer and Māori are 20% more likely to get cancer and nearly twice as likely to die from cancer as non-Māori. State-of-the-art cancer therapeutics often cost more than $100,000 per patient, putting a significant financial burden on the New Zealand healthcare budget.
This research looks at using existing New Zealand and Russian developed core technology and the existing knowledge and research and development skills of experienced national and international collaborators to evaluate a cell-based cancer vaccine therapeutic.
In the future cancer will not be a death sentence, and this project has the potential to be a step towards this healthier future.